Tecogen (TGEN) splits CEO/CFO roles, awards $1.2M in equity

Q: How many Tecogen shares were granted to CEO Dr. Abinand Rangesh?

He received 53,892 restricted shares plus options on 36,123 shares (24,075 ISOs and 12,048 NQ options).

Q: What is Roger P. Deschenes鈥� new salary as Tecogen CFO?

His annual base salary was set at $180,000 effective July 24 2025.

Q: When was the press release about the CFO appointment issued?

Tecogen issued the press release on July 28 2025 (Exhibit 99.1).

[8-K] Tecogen Inc. Reports Material Event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Tecogen (TGEN) filed an 8-K announcing governance and compensation changes dated 24 Jul 2025. The board has split the CEO and CFO/Treasurer roles; CEO Dr. Abinand Rangesh resigned as CFO/Treasurer and remains CEO & director. Roger P. Deschenes, CAO since Sept 2020 and former division CFO at L3, was appointed CFO, Principal Financial Officer and Treasurer while retaining his CAO duties, a move intended to strengthen internal controls.

Compensation adjustments: the committee raised Deschenes鈥� salary to $180k and granted equity worth 鈮�$200k (17,964 restricted shares plus 12,063 ISOs, 25 % annual vesting). Rangesh received 鈮�$600k in equity (53,892 RSAs, 24,075 ISOs, 12,048 NQ options). General Counsel John K. Whiting IV and VP Business Development Stephen Lafaille each received 鈮�$200k in equity and salary increases to $180k. All options are priced at the 24 Jul 2025 NYSE American close.

The board also authorized Dr. Rangesh to grant up to $200k in options to non-executive employees. A press release confirming Deschenes鈥� appointment was issued 28 Jul 2025 (Exhibit 99.1). No financial performance data were disclosed.

Tecogen(TGEN)鞚€ 2025雲� 7鞗� 24鞚检瀽瓯半矂雱岇姢氚� 氤挫儊氤€瓴� 靷暛鞚� 氚滍憸頃橂姅 8-K 氍胳劀毳� 鞝滌稖頄堨姷雼堧嫟. 鞚挫偓须岆姅 CEO鞕€ CFO/鞛雼措嫻鞛� 鞐暊鞚� 攵勲Μ頄堨姷雼堧嫟; CEO鞚� Dr. Abinand Rangesh電� CFO/鞛雼措嫻鞛愳鞐愳劀靷瀯頄堨溂雮� CEO 瓴� 鞚挫偓歆侅潃鞙犾頃╇媹雼�. Roger P. Deschenes電� 2020雲� 9鞗旊秬韯� CAO鞓€鞙茧┌ L3鞐愳劀攵€靹� CFO毳� 鞐瀯頃� 瓴诫牓鞚� 鞛堨溂氅�, CFO, 欤检殧鞛 毂呾瀯鞛� 氚� 鞛雼措嫻鞛�搿� 鞛勲獏霅橃柎 CAO 鞐呺霃� 瓿勳啀靾橅枆頃橂┌ 雮措秬韱奠牅臧曧檾毳� 鞙勴暅臁办箻鞛呺媹雼�.

氤挫儊臁办爼: 鞙勳洂須岆姅 Deschenes鞚� 鞐半磯鞚� 18毵� 雼煬搿� 鞚胳儊頃橁碃鞎� 20毵� 雼煬靸侂嫻鞚� 欤检嫕(鞝滍暅欤检嫕 17,964欤� 氚� 12,063 ISOs, 鞐瓣皠 25% 氩犾姢韺�)鞚� 攵€鞐枅鞀惦媹雼�. Rangesh電� 鞎� 60毵� 雼煬靸侂嫻鞚� 欤检嫕(53,892 RSA, 24,075 ISO, 12,048 牍勱车鞚� 鞓奠厴)鞚� 氚涭晿鞀惦媹雼�. 氩曤 瓿犽 John K. Whiting IV鞕€ 靷梾臧滊皽攵€靷灔 Stephen Lafaille電� 臧侁皝鞎� 20毵� 雼煬靸侂嫻鞚� 欤检嫕瓿� 鞐半磯 18毵� 雼煬鞚胳儊鞚� 氚涭晿鞀惦媹雼�. 氇摖鞓奠厴鞚€ 2025雲� 7鞗� 24鞚� NYSE American 毵堦皭臧€搿� 臧€瓴╈澊毂呾爼霅橃棃鞀惦媹雼�.

鞚挫偓须岆姅霕愴暅 Rangesh 氚曥偓鞐愱矊牍勳瀯鞗� 歆侅洂鞐愱矊斓滊寑 20毵� 雼煬靸侂嫻鞚� 鞓奠厴鞚� 攵€鞐暊甓岉暅鞚� 鞀轨澑頄堨姷雼堧嫟. Deschenes 鞛勲獏鞚� 頇曥澑頃橂姅氤措弰鞛愲電� 2025雲� 7鞗� 28鞚检棎氚滍憸霅橃棃鞀惦媹雼�(歃濌卑氍� 99.1). 鞛 靹标臣雿办澊韯半姅瓿店皽霅橃 鞎婌晿鞀惦媹雼�.

Positive

Separation of CEO and CFO/Treasurer roles strengthens governance and oversight.
Appointment of experienced finance executive Roger P. Deschenes may enhance internal controls.

Negative

Approximately 140k new restricted shares and 72k options issued to executives plus $200k option pool could create dilution.
CFO also retaining CAO position limits complete segregation of accounting and finance duties.

Insights

TL;DR 鈥� Separation of CEO/CFO improves oversight; dilution risk modest.

Splitting the CEO and CFO roles aligns Tecogen with governance best practices, reducing key-person risk and enhancing financial oversight. Deschenes brings relevant public-company experience and already knows Tecogen鈥檚 books as CAO, which should speed transition. However, he retains the CAO title, so full segregation of duties is not achieved. Equity awards total roughly $1.2 million plus $200k reserved for staff; for a micro-cap this adds slight dilution but likely under 1 % of shares outstanding. Impact: governance positive, financial impact neutral.

TL;DR 鈥� Governance upgrade, limited bottom-line effect; neutral to mildly positive.

The CFO hire signals focus on internal controls, addressing a common small-cap weakness that can weigh on valuation. Cash cost is minimal (salaries lifted to $180k), while equity awards align executives with shareholders albeit adding incremental dilution. No guidance or earnings data were provided, so operating outlook is unchanged. Market reaction should be muted unless investors previously discounted governance quality. Overall impact judged neutral-to-slightly positive.

07/28/2025 - 10:27 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 24, 2025

TECOGEN INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)


001-36103						04-3536131
(Commission File Number)						(IRS Employer Identification No.)



76 Treble Cove Road, Building 1
North Billerica, Massachusetts 01862
(Address of Principal Executive Offices and Zip Code)

(781) 466-6400

(Registrant's telephone number, including area code)

Securities registered or to be registered pursuant to Section 12(b) of the Act.


Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, $0.001 par value per share	TGEN	NYSE American, LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Section 5 - Corporate Governance and Management

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Appointment of Chief Financial Officer

On July 24, 2025, the Board of Directors of Tecogen Inc., a Delaware corporation (“Company”), determined to separate the role of Chief Executive Officer of the Company from the roles of Chief Financial Officer (“CFO”) and Treasurer, all of which executive positions have previously been held by Dr. Abinand Rangesh. In connection with such determination, Dr. Rangesh resigned as CFO and Treasurer. Following Dr. Rangesh’s resignation, the board appointed Mr. Roger P. Deschenes to serve as the Company’s Chief Financial Officer (as well as Principal Financial Officer) and Treasurer to replace Dr. Rangesh. Mr. Deschenes will continue to serve in his current position as Chief Accounting Officer (“CAO”) (as well as Principal Accounting Officer). Also, Dr. Abinand Rangesh will continue to serve as Chief Executive Officer and as a director of the Company. The appointment of Mr. Deschenes as CFO will facilitate the separation of key financial functions within the Company and is part of the Company’s efforts to enhance its internal controls over financial reporting.

Mr. Deschenes has served as the Chief Accounting Officer of the Company since September 2020. Prior to joining the Company, Mr. Deschenes served as Division CFO of L3 Security & Detection Systems, Inc., a subsidiary of L3 Harris Technologies, Inc., CFO of Implant Sciences Corporation, and CAO of Saucony, Inc.

Certain Changes in Executive Compensation

The compensation committee of the Company increased Mr. Deschenes’ annual base salary to $180,000 in connection with his appointments as CFO and Treasurer and granted equity awards to Mr. Deschenes consisting of: (i) a Restricted Stock Award of 17,964 shares of the Company’s common stock, vesting at the rate of 25% per year, and (ii) incentive stock options to purchase up to 12,063 shares of the Company’s common stock, vesting at the rate of 25% per year. The stock options have an exercise price equal to the closing sales price for the Company’s shares of common stock as reported on NYSE American LLC at the close of trading on July 24, 2025. The aggregate dollar value of the equity awards to Mr. Deschenes on the grant date is approximately $200,000.

In addition, on July 24, 2025, the compensation committee of the Company took the following actions:

1. The compensation committee made the following equity awards or grants to Dr. Rangesh: (i) a Restricted Stock Award of 53,892 shares of the Company’s common stock, vesting at the rate of 25% per year, (ii) incentive stock options to purchase up to 24,075 shares of the Company’s common stock, vesting at the rate of 25% per year, and (iii) non-qualified stock options to purchase 12,048 shares of the Company’s common stock, vesting at the rate of 25% per year.

2. The compensation committee increased the annual base salary of Mr. John K. Whiting, IV, the General Counsel and Secretary of the Company, to $180,000, and made the following equity awards or grants to Mr. Whiting: (i) a Restricted Stock Award of 11,976 shares of the Company’s common stock, vesting at the rate of 25% per year, and (ii) incentive stock options to purchase up to 24,075 shares of the Company’s common stock, vesting at the rate of 25% per year.

3. The compensation committee made the following equity awards or grants to Mr. Stephen Lafaille, the Company’s Vice President of Business of Development: (i) a Restricted Stock Award of 11,976 shares of the Company’s common stock, vesting at the rate of 25% per year, and (ii) incentive stock options to purchase up to 24,075 shares of the Company’s common stock, vesting at the rate of 25% per year.

Each stock option granted on July 24, 2025, has an exercise price per share equal to the closing sales price for the Company’s shares of common stock as reported on the NYSE American, LLC, at the close of trading on July 24, 2025. The aggregate dollar value of the equity awards to Dr. Rangesh on the grant date is approximately $600,000, and the aggregate dollar value of the equity grants to each of Messrs. Whiting and Lafaille is approximately $200,000.

Section 8 - Other Events

Item 8.01 Other Events

Appointment of Mr. Deschenes as CFO

On July 28, 2025, the Company issued a press release announcing the appointment of Mr. Deschenes as the Chief Financial Officer of the Company. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. The information in Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Securities Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act, unless expressly set forth by reference in such filing.

Non-Executive Equity Awards

On July 24, 2025, the Board of Directors delegated to Dr. Rangesh the authority to issue stock options to non-executive employees of the Company in an amount with an aggregate value not to exceed $200,000, vesting at the rate of 25% per year and with an exercise price equal to the closing sales price per share of the Company’s shares on the dates of each such grants as reported on the NYSE American LLC.

Section 9 - Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit			Description

99.1			Press Release, dated July 28, 2025 *
104			Cover Page Interactive Data File (embedded within the Inline XBRL Document)

*			Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.



	TECOGEN INC.

		By: /s/ Abinand Rangesh
July 28, 2025		Abinand Rangesh, Chief Executive Officer

Source:

FAQ

Why did Tecogen (TGEN) file an 8-K on July 28 2025?

To disclose the appointment of Roger P. Deschenes as CFO/Treasurer and related executive compensation changes.

How many Tecogen shares were granted to CEO Dr. Abinand Rangesh?

He received 53,892 restricted shares plus options on 36,123 shares (24,075 ISOs and 12,048 NQ options).

What is Roger P. Deschenes鈥� new salary as Tecogen CFO?

His annual base salary was set at $180,000 effective July 24 2025.

Will the new stock options dilute existing Tecogen shareholders?

Yes, equity awards totaling 鈮�$1.2 million plus a $200k option pool will add shares, though likely under 1 % of outstanding stock.

When was the press release about the CFO appointment issued?

Tecogen issued the press release on July 28 2025 (Exhibit 99.1).

AG真人官方

[8-K] Tecogen Inc. Reports Material Event

Insights

FAQ

Why did Tecogen (TGEN) file an 8-K on July 28 2025?

How many Tecogen shares were granted to CEO Dr. Abinand Rangesh?

What is Roger P. Deschenes鈥� new salary as Tecogen CFO?

Will the new stock options dilute existing Tecogen shareholders?

When was the press release about the CFO appointment issued?

NYSE:TGEN

TGEN Rankings

TGEN Latest News

TGEN Latest SEC Filings

TGEN Stock Data

AG真人官方

Trending News

[8-K] Tecogen Inc. Reports Material Event

Insights

Corporate Governance Expert neutral

Small-Cap Equity Analyst neutral

FAQ

Why did Tecogen (TGEN) file an 8-K on July 28 2025?

How many Tecogen shares were granted to CEO Dr. Abinand Rangesh?

What is Roger P. Deschenes鈥� new salary as Tecogen CFO?

Will the new stock options dilute existing Tecogen shareholders?

When was the press release about the CFO appointment issued?

NYSE:TGEN

TGEN Rankings

TGEN Latest News

TGEN Latest SEC Filings

TGEN Stock Data